INNOVATION FOR PATIENTS
About us

Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal disease. With the team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.

Diseases
Degenerative Disc Disease
Osteoporosis
Osteogenesis Imperfecta
Bone Metastasis
Nonunion
Osteoarthritis
Muscle Disorders
Focus on
Musculoskeletal Diseases
More information
Careers
Angita is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
More‧‧‧‧‧
Media
2024.02.28
Angitia Biopharmaceuticals Completes US$40M Second Close of Series B Extension Financing
Angitia Biopharmaceuticals, a global clinical-stage biotechnology company announces the completion of an additional US$40M Series B Extension financing in January 2024 led by YueKai Health, a market-oriented VC funded by GZHT Technology Holding and managed by Yuekai Capital. Combined with the US$46M Series B Extension financing completed in October 2023, Angitia has now raised US$86M in the Series B Extension.
2023.12.08
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
2023.10.19
Angitia Biopharmaceuticals Announces Completion of $46M Series B Extension Financing
October 19, 2023 - Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced the closing of a US$46M Series B extension financing led by Morningside Group, and syndicated by 3H Health Investment, OrbiMed, Yonghua Capital, Legend Capital, Oriza Holdings and Elikon Venture. The Series B extension financing brings the total size of the funding round to US$170M. Proceeds from the financing will be used to accelerate the global development of Angitia’s innovative drug candidates for musculoskeletal diseases including AGA111, AGA2115 and AGA2118.
more news...